Pancreatic Cancer Research

ResearcherUniversity of KansasActive in the last 2 years

Prasad R. Dandawate

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1141-3703; OpenAlex author ID A5041349401. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 10

  1. Metastatic Pancreatic Adenocarcinoma with Germline BLM and Somatic ATM Mutations: A Case Report and Review of DNA Damage Response. Co-author DOI 10.29011/2574-7754.102521↗
  2. SHP2 regulates adipose maintenance and adipocyte-pancreatic cancer cell crosstalk via PDHA1. Co-author DOI 10.1007/s12079-022-00691-1↗
  3. Anticancer Activity of Novel Difluorinated Curcumin Analog and Its Inclusion Complex with 2-Hydroxypropyl-β-Cyclodextrin against Pancreatic Cancer. Last author DOI 10.3390/ijms24076336↗
  4. Association of losartan with outcomes in metastatic pancreatic cancer patients treated with chemotherapy. Co-author DOI 10.18053/jctres.07.202102.008↗
  5. Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice. Co-author DOI 10.1053/j.gastro.2019.11.279↗
  6. Survival Outcomes of Pancreatic Intraepithelial Neoplasm (PanIN) versus Intraductal Papillary Mucinous Neoplasm (IPMN) Associated Pancreatic Adenocarcinoma. Co-author DOI 10.3390/jcm9103102↗
  7. Super-enhancers: novel target for pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.26704↗
  8. Targeting Cancer Stem Cells for Chemoprevention of Pancreatic Cancer. Co-author DOI 10.2174/0929867324666170127095832↗
  9. Quinomycin A targets Notch signaling pathway in pancreatic cancer stem cells. First author DOI 10.18632/oncotarget.6560↗
  10. Inclusion complex of novel curcumin analogue CDF and β-cyclodextrin (1:2) and its enhanced in vivo anticancer activity against pancreatic cancer. Co-author DOI 10.1007/s11095-012-0700-1↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anup Kasi · 5 shared papers, 2020–2026 · strength 0.81
  2. Shrikant Anant · 6 shared papers, 2016–2023 · strength 0.65
  3. Ravi Kumar Paluri · 2 shared papers, 2020–2026 · strength 0.43
  4. Michael Nathan VanSaun · 2 shared papers, 2023 · strength 0.35
  5. Dharmalingam Subramaniam · 4 shared papers, 2016–2020 · strength 0.34
  6. Subhash Padhyé · 4 shared papers, 2012–2023 · strength 0.32
  7. Bhargavram Channagiri Srinivas · 1 shared paper, 2026 · strength 0.32
  8. Ashish Manne · 1 shared paper, 2026 · strength 0.32
  9. Stefan H. Bossmann · 2 shared papers, 2021–2023 · strength 0.30
  10. Animesh Dhar · 3 shared papers, 2016–2020 · strength 0.23
  11. Weijing Sun · 2 shared papers, 2020–2021 · strength 0.22
  12. Appolinaire A. Olou · 1 shared paper, 2023 · strength 0.18
  13. Bailey A. Bye · 1 shared paper, 2023 · strength 0.18
  14. Mariana T. Ruckert · 1 shared paper, 2023 · strength 0.18
  15. Chandrayee Ghosh · 2 shared papers, 2019–2020 · strength 0.18
  16. Sangita Bhattacharyya · 1 shared paper, 2023 · strength 0.16
  17. Obdulia Covarrubias‐Zambrano · 1 shared paper, 2023 · strength 0.16
  18. Jessica Allen · 1 shared paper, 2021 · strength 0.14
  19. Leonidas E. Bantis · 1 shared paper, 2020 · strength 0.12
  20. Timothy McGinnis · 1 shared paper, 2020 · strength 0.12
  21. Domenico Coppola · 1 shared paper, 2020 · strength 0.08
  22. Mokenge Peter Malafa · 1 shared paper, 2020 · strength 0.08
  23. Sivapriya Ponnurangam · 1 shared paper, 2016 · strength 0.05
  24. Sanjeev Banerjee · 1 shared paper, 2012 · strength 0.03
  25. Fazlul H. Sarkar · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.